Table 2 Treatment strategies
Pulmonary embolism | Deep vein thrombosis | Odds ratio (95% CI) / P value | |
|---|---|---|---|
Patients, N | 14 | 9 | |
Duration of therapy, | |||
Mean days (SD) | 260 ± 254 | 243 ± 195 | P = 0.867 |
Median days (IQR) | 171 (111–335) | 177 (86–475) | P = 0.999 |
Initial therapy, | |||
Unfractionated heparin | 2 (14%) | 0 | – |
Low-molecular-weight heparin | 10 (71%) | 9 (100%) | – |
Mean LMWH dose (IU/kg/day) | 132 ± 50 | 151 ± 59 | P = 0.474 |
LMWH doses < 100 IU/kg/day | 4 (29%) | 2 (22%) | 2.33 (0.31–17.55) |
Rivaroxaban | 1 (7%) | 0 | – |
Inferior vena cava filter (without anticoagulant therapy) | 1 (7%) | 0 | – |
Long-term therapy, | 13 | 9 | |
Low-molecular-weight heparin | 7 (54%) | 6 (67%) | 0.58 (0. 10-3.40) |
Mean LMWH dose (IU/kg/day) | 135 ± 35 | 119 ± 43 | P = 0.491 |
LMWH < 100 IU/kg/day | 1 (8%) | 2 (22%) | 0.27 (0.02–3.52) |
Vitamin K antagonists | 5 (38%) | 3 (33%) | 1.25 (0. 21-7.41) |
Rivaroxaban | 1 (8%) | 0 | – |
No anticoagulant drugs | 0 | 0 | – |